Business
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
Submitted two additional U.S. government funding proposals during the quarter, bringing the total...
About this update from Appili Therapeutics Inc Class A
[{"type":"text","content":"Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026\n\n\n\n\n Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million\n \n\n\n\n Accepted as a new member of U.S. Medical CBRN Defense Consortium, strengthening government and biodefense partnerships\n \n\n\n\n\n HALIFAX, Nova Scotia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2026, which ended on June 30, 2025. All figures are in Canadian dollars unless otherwise stated.\n \n\n “Appili continues to strengthen our position within government and biodefense industries, highlighted by our recent participation in the\n \n U.S. Medical CBRN Defense Consortium\n \n (“MCDC”) Membership Meeting and the publication of new ATI-1701 data,” said Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics.\n \n\n “In the first quarter of fiscal 2026, we focused on building commercial momentum for LIKMEZ®, advancing ATI-1701 through ongoing funded activities, and securing a partner for ATI-1801. With seven non-dilutive funding proposals submitted to U.S. government agencies—representing up to US$137 million— Appili is positioned to advance infectious disease and biodefense products.”\n \n\n\n Update on U.S. Federal Government Funding Proposals\n \n\n\n Appili has submitted a total of seven funding proposals to U.S. government agencies, representing a potential combined award value of up to US$137 million. This includes a recently submitted proposal to the Congressionally Directed Medical Research Program’s Peer Reviewed Medical Research Program (“PRMRP”) (described herein), two proposals submitted to the U.S. Medical CBRN Defense Consortium (“MCDC”), and two proposals submitted to the National Institute of Allergy and Infectious Diseases (“NIAID”). If awarded, the funding would support the development of these projects, advancing them through manufacturing, non-cl...